Entry Point Capital, LLC Ardelyx, Inc. Call Options Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ARDX
# of Institutions
207Shares Held
143MCall Options Held
1.01MPut Options Held
1.43M-
Janus Henderson Group PLC London, X025.9MShares$156 Million0.11% of portfolio
-
Black Rock Inc. New York, NY17.6MShares$105 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.7MShares$81.9 Million0.0% of portfolio
-
State Street Corp Boston, MA12MShares$71.8 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C36.9MShares$41.4 Million0.06% of portfolio
About ARDELYX, INC.
- Ticker ARDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 154,636,000
- Market Cap $928M
- Description
- Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...